© Globe Newswire
05.12.2025
AMRX
LISTED
NASDAQ
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
News Preview
BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson’s Study Group (PSG) Annual Meeting....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2025
MURA
LISTED
NASDAQ
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
News Preview
WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasda...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
OGI
LISTED
NASDAQ
Organigram to Report Fourth Quarter Fiscal 2025 Results on December 16, 2025
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, announced today it will report earnings results for its fourth quarter fiscal 2025 ended September 30, 2025, on Tuesday, December 16, 2025, prior to market open.
The Company will host a conference call to discuss its re...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
04.12.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
News Preview
CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 1, 2025 to 24 new non-executive employees as equity inducemen...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
04.12.2025
1SXP
LISTED
XETR
SCHOTT Pharmas vorläufige Ergebnisse für das Geschäftsjahr 2025; Ausblick für das Geschäftsjahr 2026 und aktualisierte Mittelfristprognose
News Preview
SCHOTT Pharmas vorläufige Ergebnisse für das Geschäftsjahr 2025; Ausblick für das Geschäftsjahr 2026 und aktualisierte Mittelfristprognose
Vorläufige Ergebnisse für das Geschäftsjahr 2025 entsprechen der Prognose:
Umsatz von 986,2 Mio. Euro (währungsbereinigtes Wachstum von 5,8 %)
EBITDA-Marge steigt auf 28,4 % (Vorjahr: 26,9 %) währungsberein......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
1SXP
LISTED
XETR
Outlook for fiscal year 2026 and update of mid-term guidance
News Preview
SCHOTT Pharma: Outlook for fiscal year 2026 and update of mid-term guidance
Today, SCHOTT Pharma issues its financial guidance for fiscal year 2026: The company expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%. This projection deviates from current market expectations (source: Vara consensus as o......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
1SXP
LISTED
XETR
Ausblick für das Geschäftsjahr 2026 und Aktualisierung der mittelfristigen Prognose
News Preview
SCHOTT Pharma: Ausblick für das Geschäftsjahr 2026 und Aktualisierung der mittelfristigen Prognose
Für das Geschäftsjahr 2026 erwartet SCHOTT Pharma ein währungsbereinigtes Umsatzwachstum im Bereich von 2-5% sowie eine EBITDA-Marge von rund 27%. Diese Prognose weicht von den aktuellen Markterwartungen von 8,2% währungsbereinigtem Wachstum und einer......
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
COLO B
LISTED
CPH
Coloplast A/S - Decisions at the Annual General Meeting 2025
News Preview
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
CTXR
LISTED
NASDAQ
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
News Preview
Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAELYMPHIR international availability extends to 19 markets outside the U.S.CRANFORD, N.J., Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
UCB
LISTED
EURONEXT
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
News Preview
Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including the presentation of positive primary efficacy and safety results from a phase 3 study of FINTEPLA® (fenfluramine)1 in CDD, marking the third developmental and epileptic encephalopathy (DEE) to see positive results following Dravet syndrome (DS) and Lenno...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
SECT_B
LISTED
STO
Swedish health care region expands with Sectra and digitizes pathology for advanced cancer care
News Preview
LINKÖPING, Sweden, Dec. 4, 2025 /PRNewswire/ -- The Swedish healthcare provider Region Halland will expand its use of international medical imaging IT and cybersecurity company Sectra's (STO: SECT B) solutions by adding digital pathology. Replacing microscopes with a digital workflow will provide them with instant remote access to images, facilita...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
SOBI
LISTED
STO
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN
News Preview
Robust and clinically meaningful benefits observed across all three key markers of disease – 68% reduction in proteinuria, stabilisation of kidney function, and substantial clearance of C3 deposits. Consistent results across C3G and primary IC-MPGN, adults and adolescents, and native and post-transplant kidney disease. Pegcetacoplan is under regul...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
04.12.2025
EVT
LISTED
XETR
Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome
News Preview
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome
Milestone payment to Evotec expected upon first dosing of first study participant in early 2026
Hamburg, Germany, 04 December 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 56......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
EVT
LISTED
XETR
Evotec-Partner Bayer startet Phase-2-Studie zur Behandlung von Patienten mit Alport-Syndrom
News Preview
Klinische Studie der Phase 2 begonnen, um das Potenzial eines SEMA3A-Antikörpers als mögliche Behandlung für das Alport-Syndrom zu bewerten
Meilensteinzahlung an Evotec nach erster Verabreichung der Prüfsubstanz an den ersten Studienteilnehmenden für Anfang 2026 erwartet
Hamburg, 04. Dezember 2025:
Evotec SE (Frankfurter Wertpapierbör......
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2025
BAYN
LISTED
XETR
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
News Preview
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a rando...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
BIOA B
LISTED
STO
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
News Preview
STOCKHOLM, Dec. 4, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's Disease (CTAD) conference, held in San Diego December 1-4. Data suggests potential to delay disease progress...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
BIOA B
LISTED
STO
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
News Preview
STOCKHOLM, Dec. 4, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab (Leqembi®) at the 18th Clinical Trials in Alzheimer's Disease (CTAD) conference, held in San Diego December 1-4. Data suggests potential to delay disease progress...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
AGFB
LISTED
EURONEXT
Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market
News Preview
December 4, 2025 – 7:45 a.m. CET Regulated information...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
FYB
LISTED
XETR
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
News Preview
Presse Release // December 04, 2025
Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
Planegg-Martinsried, Germany / Amman, Jordan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and suppl......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2025
FYB
LISTED
XETR
Formycon und MS Pharma schließen exklusive Kommerzialisierungspartnerschaft für den Keytruda®-Biosimilar-Kandidaten FYB206 in der MENA-Region
News Preview
Pressemitteilung // 04. Dezember 2025
Formycon und MS Pharma schließen exklusive Kommerzialisierungspartnerschaft für den Keytruda®-Biosimilar-Kandidaten FYB206 in der MENA-Region
Planegg-Martinsried, Deutschland / Amman, Jordanien – Die Formycon AG (FWB: FYB, Prime Standard) und MS Pharma geben gemeinsam bekannt, dass sie eine exklusive Lizenz- ......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
04.12.2025
EVT
LISTED
XETR
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
News Preview
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBURG, DE / ACCESS Newswire / December 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NAS...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
MURA
LISTED
NASDAQ
Mural Oncology Announces Sanction of the Scheme by the High Court
News Preview
WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) pursuant to which XRA 5 Corp. (“Sub”), a wholly-owne...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
GMAB
LISTED
CPH
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2025
BAYN
LISTED
XETR
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
News Preview
Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhance...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2025
LIVN
LISTED
NASDAQ
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2025
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – INSP
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Inspire Medical Systems, Inc. (“Inspire” or “the Company”) (NYSE: INSP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of INSP dur...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - from First Berlin Equity Research GmbH
03.12.2025 / 10:58 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2025
EUZ
LISTED
XETR
Eckert & Ziegler und SK Biopharmaceuticals unterzeichnen Liefervertrag für Actinium-225
News Preview
Berlin, Deutschland & Seoul, Südkorea, 3. Dezember 2025. Eckert & Ziegler (ISIN DE0005659700, TecDAX) und SK Biopharmaceuticals, ein auf Therapien für Erkrankungen des Zentralnervensystems (ZNS) spezialisiertes Biotechnologieunternehmen mit Sitz in Südkorea, das ebenfalls im Bereich Radiopharmazeutika tätig ist, haben kürzlich einen Lieferv......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2025
EUZ
LISTED
XETR
Eckert & Ziegler and SK Biopharmaceuticals Sign Actinium-225 Supply Agreement
News Preview
Berlin, Germany & Seoul, South Korea, 3 December 2025 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed a supply agreement with SK Biopharmaceuticals, a biotech company specializing in research, development, and commercialization of treatments of central nervous system (CNS) disorder, active in the field of radiopharma and based in ......
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
CLARI
LISTED
EURONEXT
Disposal of 9 real estate assets in Belgium
News Preview
...
Themefolio
Profiler
Peergroup
© Newsfile
03.12.2025
COPN
LISTED
SIX
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
News Preview
Ad hoc announcement pursuant to Art. 53 LR 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805) Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo an...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2025
ORNBV
LISTED
HEL
Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 3 DECEMBER 2025 at 09.00 EET ...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
EHAB
LISTED
NYSE
Enhabit Announces Participation in Bank of America Home Care Conference 2025
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Bank of America Home Care Conference 2025.
Enhabit’s President and CEO Barb Jacobsmeyer and Chief Financial Officer Ryan Solomon will participate in a fireside chat on Tuesday, Dec. 9, at 2:50 p.m. CT. The fireside chat will b...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
TLRY
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - TLRY
News Preview
TORONTO, Dec. 2, 2025 /CNW/ - Trading resumes in:
Company: Tilray Brands, Inc.TSX Symbol: TLRYAll Issues: NoResumption (ET): 10:57:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
TLRY
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - TLRY
News Preview
TORONTO, Dec. 2, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: Tilray Brands, Inc.TSX Symbol: TLRYAll Issues: NoReason: Single Stock Circuit BreakerHalt Time (ET): 10:52:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented t...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
ERF
LISTED
EURONEXT
Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices
News Preview
Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical devic...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
LIVN
LISTED
NASDAQ
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team.
“Lucile is an accomplish...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
BAYN
LISTED
XETR
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
News Preview
Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women.
NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, d...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
ICLR
LISTED
NASDAQ
ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines.
The sur...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
ACB
LISTED
NASDAQ
Aurora Announces Distribution Partnership with Leafio Australia
News Preview
The collaboration will improve medical cannabis access and better serve patients across AustraliaNASDAQ | TSX: ACBEDMONTON, AB, Dec. 2, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entered into...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
ACB
LISTED
NASDAQ
Aurora Announces Distribution Partnership with Leafio Australia
News Preview
The collaboration will improve medical cannabis access and better serve patients across AustraliaNASDAQ | TSX: ACBEDMONTON, AB, Dec. 2, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entere...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2025
AMRX
LISTED
NASDAQ
Amneal to Participate in Upcoming Investor Conferences
News Preview
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
BAYN
LISTED
XETR
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
News Preview
Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control to tough pathogens, like ascochyta, while also keeping the user ease of use top of mind.
This press release features multimedia. View the full re...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2025
KDEV
LISTED
STO
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
News Preview
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Thursday January 8, 2026, at 10.00 a.m. (CET), at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2025
BAVA
LISTED
CPH
Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million
News Preview
Bavarian Nordic intends to launch a one-time share buy-back program of up to DKK 500 million...
Themefolio
Profiler
Peergroup
© PR Newswire
01.12.2025
KPTI
LISTED
NASDAQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock and an aggregate of 15,791 restricted stock units (RSUs)...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2025
MNMD
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grants
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 182,100 common...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
GMAB
LISTED
CPH
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
AMRX
LISTED
NASDAQ
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
News Preview
BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generi...
Themefolio
Profiler
Peergroup
© PR Newswire
01.12.2025
CTXR
LISTED
NASDAQ
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
News Preview
LYMPHIR now available nationwideCRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-direc...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2025
BAYN
LISTED
XETR
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
News Preview
Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide),...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
ZEAL
LISTED
CPH
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025
News Preview
Press release – No. 17 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
RXRX
LISTED
NASDAQ
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
News Preview
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on Decembe...
Themefolio
Profiler
Peergroup
© PR Newswire
01.12.2025
KPTI
LISTED
NASDAQ
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
News Preview
NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 37th Annual Healthcare Conference in a fireside chat on Thursday, December 4, 2025 at 1...
Themefolio
Profiler
Peergroup
© ActuNews
01.12.2025
OXUR
LISTED
EURONEXT
Oxurion secures a binding EUR 30 million financing facility dedicated to investments in digital and crypto assets
News Preview
Leuven, BELGIUM – December 1 , 2025 – 08:00 AM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces the signing of a subscription agreement with Atlas Capital Markets for a financing via convertible bonds, for a total amount of €30 million, divided into 12 tranches of ...
Themefolio
Profiler
Peergroup
© ActuNews
01.12.2025
OXUR
LISTED
EURONEXT
Oxurion sécurise un financement ferme de 30 millions d'euros dédié à des investissements dans les actifs numériques et crypto actifs
News Preview
Louvain, BELGIQUE – 1er décembre 2025 – 8h00, Oxurion NV (Euronext Bruxelles : OXUR), société de sous-traitance pharmaceutique basée à Louvain, annonce la signature d'un accord de souscription avec Atlas Capital Markets portant sur un financement en obligations convertibles d'un montant total d...
Themefolio
Profiler
Peergroup
© ActuNews
01.12.2025
OXUR
LISTED
EURONEXT
Oxurion verzekert een bindende financieringsfaciliteit van EUR 30 miljoen voor investeringen in digitale activa en crypto activa
News Preview
Leuven, BELGIË – 1 december 2025 – 8u00 CET Oxurion NV (Euronext Brussel: OXUR), een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, kondigt de ondertekening aan van een inschrijvingsovereenkomst met Atlas Capital Markets betreffende een financiering via converteerbare obligaties, voor een totaalbedrag van &eur...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
KDEV
LISTED
STO
Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER...
Themefolio
Profiler
Peergroup
© BusinessWire
28.11.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
